Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

Ge HongYan; Li PeiXia; Zhang YangYang; Wang LiLi; Wei YaoLing

doi:10.3969/j.issn.1001-5256.2018.01.020

Issue 1

Jan. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(1): 97-100

PDF( 1566 KB)

Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2018.01.020

Department of Gastroenterology, Affiliated Hospital of Inner Mongolia University for The Nationalities, Tongliao, Inner Mongolia 028000, China

Published Date: 2018-01-20

Abstract

Abstract

Objective To investigate the clinical effect of octreotide combined with an increased amount of fluid infusion in the treatment of intractable cirrhotic ascites, and to provide new thoughts for clinical diagnosis and treatment. Methods A total of 65 patients with intractable cirrhotic ascites who visited Affiliated Hospital of Inner Mongolia University for The Nationalities from February 2016 to May 2017 were enrolled and randomly divided into control group with 31 patients and observation group with 34 patients. The patients in the control group were given conventional treatment, and those in the observation group were given continuous pumping of octreotide 0. 6 mg once every 12 hours for 3 days, followed by intramuscular injection of octreotide 0. 2 mg once every 8 hours for 7-10 consecutive days, and an increased amount of fluid infusion, in addition to the conventional treatment. Symptomatic treatment was given based on patients' symptoms and tolerance. Vital signs, abdominal circumference, body weight, and time to ascites regression were observed during treatment, and the length of hospital stay and incidence rate of complications were analyzed. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results Compared with the control group, the observation group had significantly shorter time to ascites regression ( 6. 13 ± 1. 25 d vs 11. 61 ± 1. 34 d, t =-4. 06, P < 0. 001) and length of hospital stay ( 10. 01 ± 1. 46 d vs 16. 10 ± 1. 57 d, t =-7. 65, P < 0. 001) , as well as significantly greater average daily reductions in abdominal circumference ( 4. 01 ± 0. 75 cm vs 2. 42 ± 0. 35 cm, t = 4. 69, P < 0. 001) and body weight ( 1. 67 ± 0. 42 kg vs 0. 97 ± 0. 54 kg, t = 4. 58, P < 0. 001) . The observation group had significantly lower incidence rates of upper gastrointestinal bleeding and electrolyte disturbance than the control group ( upper gastrointestinal bleeding: 5. 88% vs 32. 26% , χ2= 7. 49, P < 0. 05; electrolyte disturbance: 8. 82% vs 38. 71% , χ2= 8. 56, P < 0. 05) . Conclusion In addition to the conventional treatment of intractable ascites, octreotide combined with an increased amount of fluid infusion can promote spontaneous dieresis, significantly reduce the amount of ascites, shorten the time to ascites regression, reduce complications, and improve patients' conditions.
- liver cirrhosis,
- ascites,
- octreotide,
- fluid therapy,
- treatment outcome

FullText(HTML)

References(15)

References

[1]ARROYO V, GINES P, GERBES AL, et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J].Hepatology, 1996, 23 (1) :164-176.

[2]CHEN Y, ZHOU L.Research advances in treatment of cirrhotic ascites[J].J Clin Hepatol, 2016, 32 (6) :1069-1074. (in Chinese) 陈煜, 周莉.肝硬化腹水治疗的新进展[J].临床肝胆病杂志, 2016, 32 (6) :1069-1074.

[3]SANGIOVANNI A, PRATI GM, FASANI P, et al.The natural history of compensated cirrhosis due to hepatitis C virus:a 17-year cohort study of 214 patients[J].Hepatology, 2006, 43 (6) :1303-1310.

[4]GE JB, XU YJ.Internal Medicine[M].8th ed.Beijing:People's Medical Publishing House, 2013:419-428. (in Chinese) 葛均波, 徐永健.内科学[M].8版.北京:人民卫生出版社, 2013:419-428.

[5]LIN PC, LIN YK, LI YB, et al.Advances in the treatment of cirrhotic ascites[J].Mod J Integr Tradit Chin West Med, 2014, 23 (29) :3299-3301. (in Chinese) 林培淳, 林勇凯, 李艺滨, 等.肝硬化腹水治疗进展[J].现代中西医结合杂志, 2014, 23 (29) :3299-3301.

[6]OCHS A, ROSSLE M, HAAG K, et al.The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites[J].N Engl J Med, 1995, 332 (18) :1192-1197.

[7]SINGHAL S, BAIKATI KK, JABBOUR II, et al.Management of refractory ascites[J].Am J Ther, 2012, 19 (2) :121-132.

[8]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[9]LIU HH, LUO SQ, FU JL, et al.Advances in the treatment of intractable cirrhotic ascites[J].J Pract Hepatol, 2011, 14 (4) :317-320. (in Chinese) 刘红虹, 罗生强, 福军亮, 等.肝硬化顽固性腹水的治疗新进展[J].实用肝脏病杂志, 2011, 14 (4) :317-320.

[10]SCHRIER RW.Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy[J].N Engl J Med, 1988, 319 (17) :1127-1134.

[11]FORTUNE B, CARDENAS A.Ascites, refractory ascites and hyponatremia in cirrhosis[J].Gastroenterol Rep (Oxf) , 2017, 5 (2) :104-112.

[12]ZHANG JL, LIU JL, LI YG, et al.The treatment discussion of refractory ascites in the cirrhosis of the liver[J].J World Latest Med Inf, 2016, 16 (100) :52-53, 56. (in Chinese) 张俊立, 刘静丽, 李艳歌, 等.肝硬化难治性腹水的治疗探讨[J].世界最新医学信息文摘, 2016, 16 (100) :52-53, 56.

[13]GUO LX.Clinical treatment in patients with liver cirrhosis refractory ascites[J].Chin Community Doct, 2016, 32 (35) :56, 58. (in Chinese) 郭丽仙.肝硬化难治性腹水的临床治疗观察[J].中国社区医师, 2016, 32 (35) :56, 58.

[14]ZHANG GQ.An analysis of clinical therapies for cirrhotic ascites[J].Chin J Mod Drug Appl, 2017, 11 (3) :133-135. (in Chinese) 张桂芹.肝硬化腹水临床的治疗方法分析[J].中国现代药物应用, 2017, 11 (3) :133-135.

[15]ZHU Q, JIANG XH, YI F, et al.The effects of octreotide on portal hemodynamics in patients with liver cirrhosis[J].Chin J Intern Med, 2004, 43 (1) :16-18. (in Chinese) 诸琦, 江晓华, 乙芳, 等.奥曲肽对肝硬化门脉血流动力学的影响[J].中华内科杂志, 2004, 43 (1) :16-18.

Relative Articles

[1]	Lanjing WANG, Xin YAO, Jianping QIN, Shanhong TANG. TIPS for treatment of refractory ascites in cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2606-2610. doi: 10.3969/j.issn.1001-5256.2022.11.034
[2]	Yu TIAN, Jia HONG, Bingqiong WANG, Hong YOU. Current status and prospects of long-term albumin treatment in patients with cirrhotic ascites[J]. Journal of Clinical Hepatology, 2021, 37(1): 173-175. doi: 10.3969/j.issn.1001-5256.2021.01.037
[3]	Li Shuang, Tao YanYan, Xing Feng, Zhao Qiang, Liu ChengHai. Effect of Xiaozhang plaster in treatment of cirrhotic ascites and its influence on the renin-angiotensin-aldosterone system[J]. Journal of Clinical Hepatology, 2019, 35(7): 1496-1500. doi: 10.3969/j.issn.1001-5256.2019.07.015
[4]	Ji HuiChun, Zhang ZhenJiang, Zhu Fang, Liu JunQuan, Liu QingDe, Pang Wei. Clinical effect of alprostadil combined with entecavir in treatment of HBV-related liver failure complicated by ascites[J]. Journal of Clinical Hepatology, 2016, 32(11): 2151-2154. doi: 10.3969/j.issn.1001-5256.2016.11.030
[5]	Chen Yu, Zhou Li. Research advances in treatment of cirrhotic ascites[J]. Journal of Clinical Hepatology, 2016, 32(6): 1069-1074. doi: 10.3969/j.issn.1001-5256.2016.06.009
[6]	Zhang WenWen, Qi XingShun, Guo XiaoZhong. Mirabilite umbilical compress in treatment of ascites in liver cirrhosis: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(6): 947-950. doi: 10.3969/j.issn.1001-5256.2015.06.028
[7]	Zhan GuoQing, Li Fang, Li RuGui, Guo Peng, Liu Xiang, Zhang WeiWei, Tan HuaBing. Efficacy of terlipressin therapy for refractory ascites in cirrhosis and type-2 hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2015, 31(8): 1287-1290. doi: 10.3969/j.issn.1001-5256.2015.08.025
[8]	Xia YuLian, Zhang ChunQing, Wang GuangChuan, Feng Hua, Zhang MingYan. Individual and combined effects of octreotide and terlipressin on hepatic venous pressure gradient in cirrhotic patients[J]. Journal of Clinical Hepatology, 2015, 31(2): 214-218. doi: 10.3969/j.issn.1001-5256.2015.02.017
[9]	Zhang YuHuai, Luo ZhangJiang. Efficacy and safety of octreotide in treatment of hepatocellular carcinoma: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(6): 922-926. doi: 10.3969/j.issn.1001-5256.2015.06.023
[10]	Liu ChengHai, Xing Feng. The potential benefit managing ascites due to cirrhosis using an integrative medicine approach[J]. Journal of Clinical Hepatology, 2013, 29(4): 253-256.
[11]	Wu HaiQing, Wang Hui. Diagnosis and treatment of spontaneous bacterial peritonitis in patients with liver ascites[J]. Journal of Clinical Hepatology, 2012, 28(9): 651-653.
[12]	Hu LiJuan, Wang LiJing, Jian YiCheng, Xiong WuJun. Efficacy of octreotide treatment for chylous ascites after liver cirrhosis: A case report and literature review[J]. Journal of Clinical Hepatology, 2012, 28(8): 624-625.
[13]	Shi HaiDong. Clinical observation of alprostadil injection in the treatment of liver cirrhosis with jaundice[J]. Journal of Clinical Hepatology, 2011, 27(9): 962-964.
[14]	Yuan ShanShan, Han GuoHong, Bo Ming, He ChuangYe, Yin ZhanXin, Wang JianHong, Qi XingShun, Yang ZhiPing, Zhang Wei. Prognostic factors in the prediction of survival following TIPS for cirrhosis and refractory ascites[J]. Journal of Clinical Hepatology, 2011, 27(5): 525-527.
[15]	Zhang Jian, Wang ZhaoQuan. One case of conservative treatment for inguinal umbilical hernia with ascites of hepatocirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 314-315.
[16]	Qiu Ling, Hu YuLin. Recent status and prospect of ascites treatment in cirrhosis patients[J]. Journal of Clinical Hepatology, 2010, 26(6): 663-665.
[17]	Zhan GuoQing, Tan HuaBing, Li RuGui, Du WeiXing, Li Gang, Zhu Lin. The efficacy of mannital combined with dopamine for the treatment of refractory ascites in cirrhosis[J]. Journal of Clinical Hepatology, 2009, 25(6): 424-426.
[19]	Li YouTian, Li Yang, Li Bing. Effect of combination of traditional chinese medicine and western medicine on ascites resulted from liver cirrhosis[J]. Journal of Clinical Hepatology, 2003, 19(3): 150-151.

Supplements(0)

Cited By

Cited by

Periodical cited type(10)

1.	雷后胜. 奥曲肽联合加大补液量在肝硬化难治性腹水中的作用. 航空航天医学杂志. 2024(12): 1450-1453 .
2.	王慧玲，丁晓. 早期限制性液体复苏对肝硬化上消化道出血的复苏成功率及预后影响. 青岛医药卫生. 2022(01): 50-52 .
3.	卢春燕，吴雄健. 肝硬化腹水的药物疗法. 赣南医学院学报. 2022(04): 396-398 .
4.	杨梅，王谦. 奥曲肽联合西咪替丁治疗上消化道出血患者的效果及对止血时间、血小板计数的影响. 临床医学研究与实践. 2021(07): 66-68 .
5.	刘聪. 奥曲肽联合奥美拉唑对上消化道出血的疗效探讨. 系统医学. 2021(02): 56-58 .
6.	刁利霞，莫冬林，吴宇平. 奥曲肽结合加大补液量治疗肝硬化难治性腹水的效果及对其血清学指标的影响. 北方药学. 2020(01): 55-56 .
7.	张兵，邓丹. 肝硬化难治性腹水的临床治疗效果分析. 中国继续医学教育. 2019(05): 113-115 .
8.	马陈斌. 肝硬化腹水的临床治疗应用效果观察. 世界最新医学信息文摘. 2019(27): 72+83 .
9.	何清辉. 前列地尔辅助治疗肝硬化难治性腹水的可行性分析. 慢性病学杂志. 2019(07): 1039-1041 .
10.	李青，孙咏红. 托伐普坦治疗顽固性腹水患者临床疗效及安全性. 中国实用医药. 2018(32): 131-133 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2604) PDF downloads(406)

Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2018.01.020